Nature Immunology - Issue - nature.com science feeds
Nature Immunology, Published online: 22 October 2024; doi:10.1038/s41590-024-01994-8In this Resource, Buckley and colleagues profile patients with Crohn’s disease and ulcerative colitis before and after adalimumab therapy. Specific pretreatment differences in the epithelial and myeloid compartments were associated with remission outcomes in both diseases....
Nature Immunology, Published online: 18 October 2024; doi:10.1038/s41590-024-01995-7Gámez-García et al. show that the deacetylase SIRT7 modulates the acetylation of Pax5 and its ability to repress alternate lineage programs and promote B cell differentiation and commitment in B cell progenitor cells.
Nature Immunology, Published online: 16 October 2024; doi:10.1038/s41590-024-01987-7Using temporal and spatial tracking of allergen-specific T cells, we describe the gene regulatory networks that drive T helper 2 cells (TH2 cells) to develop in response to allergens. Spatial microniches of IL-2 in lymph nodes supported the earliest TH2 cells, demonstrating...
Nature Immunology, Published online: 16 October 2024; doi:10.1038/s41590-024-01991-xThe interplay of metabolites with epigenetic programs influences CD8+ T cell fate decisions. Here, Raychaudhuri et al. show that lactate-dependent histone lactylation tunes CD8+ T cell metabolism and function by regulating epigenetic and transcriptional remodeling.
Nature Immunology, Published online: 15 October 2024; doi:10.1038/s41590-024-01977-9The Irf8 +32-kb enhancer controls transcriptional autoactivation to generate ‘IRF8 on’ and ‘IRF8 off’ states that define type 1 conventional dendritic cell (cDC1) and cDC2 lineages, respectively. Weak affinity of this enhancer for BATF3–JUNB–IRF8 complexes allows specified...
Nature Immunology, Published online: 15 October 2024; doi:10.1038/s41590-024-01993-9CAR-T cells are revolutionizing the treatment of cancer and other diseases. A latest iteration in development involves fusion with an antigen-based CAR enhancer to provide low-affinity IL-2 signaling that might limit adverse effects.
Build your own newsfeed
Ready to give it a go?
Start a 14-day trial, no credit card required.